Septerna (SEPN) Total Non-Current Liabilities (2023 - 2026)
Septerna's (SEPN) quarterly Total Non-Current Liabilities came in at $191.1 million in Q1 2026, up 466.7% year-on-year from $33.7 million in Q1 2025, and down 10.8% quarter-over-quarter from $214.3 million in Q4 2025.
Septerna (SEPN) Total Non-Current Liabilities (2023 - 2026) Analysis & Trends
Septerna's Total Non-Current Liabilities history runs 4 years deep, the most recent figure standing at $191.1 million for Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities rose 466.7% year-over-year to $191.1 million in Q1 2026; TTM through Mar 2026 was $191.1 million, a 466.7% increase from a year earlier, with the FY2025 full-year figure at $214.3 million, up 487.43% from the prior year.
- Total Non-Current Liabilities fell to $191.1 million in Q1 2026 per SEPN's latest filing, from $214.3 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $217.9 million in Q3 2025 and bottomed at $19.5 million in Q4 2023.
- The 4-year median for Total Non-Current Liabilities is $37.5 million (2024), against an average of $98.5 million.
- Across the five-year window, Total Non-Current Liabilities soared 87.24% in 2024 and soared 487.43% in 2025, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $19.5 million in 2023, then soared by 87.24% to $36.5 million in 2024, then surged by 487.43% to $214.3 million in 2025, then slipped by 10.8% to $191.1 million in 2026.
- Per Business Quant, the three latest SEPN Total Non-Current Liabilities figures stand at $191.1 million (Q1 2026), $214.3 million (Q4 2025), and $217.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Septerna | 1.50 Bn | 1.50 Bn | - | 191.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 191.13 Mn |
| Dec 31, 2025 | 214.26 Mn |
| Sep 30, 2025 | 217.92 Mn |
| Jun 30, 2025 | 37.67 Mn |
| Mar 31, 2025 | 33.73 Mn |
| Dec 31, 2024 | 36.47 Mn |
| Sep 30, 2024 | 37.34 Mn |
| Dec 31, 2023 | 19.48 Mn |